Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has ...

Merck rose 1.17% on a trading day, showcasing a volume of $870M and a 121st rank in activity. Analysts are sending mixed ...

The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and healthcare segments, but was more cautious on sales.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

With U.S. markets hovering near record highs, many investors are turning to dividend-paying stocks as a way to balance growth ...

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck 's (NYSE ...